Co-exporge tablets 10 + 160 + 12.5mg, No. 28
Expiration Date: 05/2027
Russian Pharmacy name:
Ко-эксфорж таблетки 10+160+12,5мг, №28
Arterial hypertension II and III degree.
Inside (preferably in the morning) with a small amount of water, regardless of the meal.
For convenience, patients receiving therapy with amlodipine, valsartan and hydrochlorothiazide in separate tablets can be switched to therapy with Co-Exforge containing the same doses of active ingredients, as well as with insufficient blood pressure control against the background of double combination therapy (valsartan + hydrochlorothiazide, amlodipine + valsartan and amlodipine + hydrochlorothiazide), patients can be transferred to a triple combination treatment with Co-Exforge in appropriate doses.
If a patient has dose-dependent side effects when using a double combination therapy with any of the components of Co-Exforge, to achieve a similar decrease in blood pressure, patients can be prescribed Co-Exforge, containing a lower dose of the active component that caused this side effect.
Recommended daily doses of Co-Exforge:
- 5 + 160 + 12.5 mg (1 tablet containing amlodipine + valsartan + hydrochlorothiazide in doses of 5 + 160 + 12.5 mg);
- 10 + 160 + 12.5 mg (1 tablet containing amlodipine + valsartan + hydrochlorothiazide in doses of 5 + 160 + 12.5 mg);
- 10 + 320 + 25 mg (2 tablets containing amlodipine + valsartan + hydrochlorothiazide in doses of 5 + 160 + 12.5 mg).
The maximum antihypertensive effect of the drug is observed 2 weeks after increasing the dose. The maximum dose of the drug is 10 + 320 + 25 mg / day.
Patients over 65 years of age. No dose adjustment is required.
Children and adolescents under the age of 18. Since the safety and efficacy of Co-Exforge in children and adolescents (under 18 years of age) have not yet been established, the drug is not recommended for use in this category of patients.
Patients with impaired renal or hepatic function. In patients with mild to moderate renal impairment (Cl creatinine more than 30 ml / min) and liver (5-9 points on the Child-Pough scale), dose adjustment is not required.
| Film-coated tablets | 1 tab. |
| active substance: | |
| amlodipine besilate | 6.94 mg |
| (corresponds to 5 mg of amlodipine base) | |
| 13.87 mg | |
| (corresponds to 10 mg of amlodipine base) | |
| valsartan | 160 mg |
| hydrochlorothiazide | 12.5 mg |
| excipients: MCC; crospovidone; colloidal silicon dioxide; magnesium stearate | |
| film shell: hypromellose; titanium dioxide (E171); macrogol; talc | |
| film shell additionally for table. 10 + 160 + 12.5 mg: iron dye yellow oxide (E172), iron dye red oxide (E172) |
hypersensitivity to amlodipine, valsartan, hydrochlorothiazide, other sulfonamide derivatives, dihydropyridine derivatives and other auxiliary components of the drug;
pregnancy and the period of breastfeeding;
severe liver dysfunction (more than 9 points on the Child-Pough scale);
severe dysfunction of the night (Cl creatinine less than 30 ml / min), anuria;
hypokalemia, hyponatremia, hypercalcemia, and also hyperuricemia with clinical manifestations, refractory to adequate therapy;
age up to 18 years (efficacy and safety have not been established).
Carefully:
unilateral or bilateral renal artery stenosis or stenosis of a solitary kidney artery;
conditions accompanied by a decrease in the BCC;
violations of water and electrolyte balance (including hyponatremia, hyperkalemia);
mitral or aortic stenosis, and hypertrophic obstructive cardiomyopathy;
mild to moderate liver dysfunction, especially against the background of biliary obstruction (less than 9 points on the Child-Pough scale);
diabetes;
systemic lupus erythematosus.
The safety of using the drug in patients after recent kidney transplantation, as well as in patients with heart failure or coronary heart disease has not been established.